Sheldon P W, Hill S A
Br J Cancer. 1977 Aug;36(2):198-205. doi: 10.1038/bjc.1977.178.
The tumour used, designated MT1, is a more radiosensitive form of the anaplastic MT tumour previously described. No explanation for the increased radiosensitivity was found, but it was shown not to be due to infection or to a change in immunological status, growth rate or histology. The sensitivity has remained constant throughout the present work. No cytotoxicity in the tumour was observed when 1 mg/g body weight of Ro-07-0582 was injected immediately after a single dose of X-rays; indeed a small protective effect was seen. A radiosensitization enhancement of 1-5 was achieved with a relatively low drug dose of Ro-07-0582 in a 5F/4d fractionated regime. The interval between the injection of a low dose of Ro-07-0582 and the start of irradiation was found to be critical, the optimum interval being 45-60 min. The subsequent incidence of distant metastases was not increased by the use of Ro-07-0582 at the time of "primary" tumour irradiation.
所使用的肿瘤命名为MT1,是先前所述间变性MT肿瘤中对辐射更敏感的一种形式。未发现辐射敏感性增加的原因,但已表明这并非由于感染或免疫状态、生长速率或组织学的改变所致。在目前的研究工作中,这种敏感性一直保持不变。在单次X射线剂量照射后立即注射1毫克/克体重的Ro-07-0582时,未观察到肿瘤有细胞毒性;实际上还观察到了轻微的保护作用。在5F/4d分次照射方案中,使用相对较低剂量的Ro-07-0582可实现1至5倍的放射增敏增强效果。发现低剂量Ro-07-0582注射与开始照射之间的间隔至关重要,最佳间隔为45至60分钟。在“原发性”肿瘤照射时使用Ro-07-0582,并未增加远处转移的后续发生率。